eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | hepatitis c |
| Symptom | C0151317|chronic infection |
| Sentences | 115 |
| PubMedID- 22878466 | Mental health problems frequently occur in chronic infection with the hepatitis c virus (hcv) and during antiviral treatment with pegylated interferon-alpha (pegifnalpha) and ribavirin. |
| PubMedID- 19773667 | Objectives: although chronic infection with the hepatitis c virus (hcv) may lead to the development of cirrhosis and its complications, little data are available on progression to the decompensated stage in a hetereogeneous population. |
| PubMedID- 22158321 | In addition to these associations, there is substantial evidence for a causativerelationship between chronic infection with hepatitis c virus (hcv) and non-hodgkinlymphoma (nhl), an association that has been the subject of several recentsystematic reviews (gisbert et al, 2003;matsuo et al, 2004; dal maso and franceschi, 2006). |
| PubMedID- 22039483 | For example, chronic infection with hepatitis c virus (hcv) results from reduction of the dimerization of mitochondrial antiviral signaling protein (mavs) by hcv nonstructural (ns) protein ns3/4a protease to levels that are too low to mount strong enough antiviral immune responses . |
| PubMedID- 21449783 | Background: peginterferon-ribavirin therapy is the current standard of care for chronic infection with hepatitis c virus (hcv). |
| PubMedID- 26058595 | In japan, most european countries, and america, approximately 60% of hcc cases are attributed to chronic infection with hepatitis c virus (hcv) 3. |
| PubMedID- 20108989 | chronic infection with hepatitis c virus (hcv) is a major healthcare problem, affecting an estimated 170 million people worldwide. |
| PubMedID- 21813371 | chronic infection with the hepatitis c virus (hcv) affects more than 3% of the world's population 1. |
| PubMedID- 21645344 | In this article we discuss several liver conditions which are directly affected by overweight and obese status, including non-alcoholic fatty liver disease, chronic infection with hepatitis c virus and post-liver transplant status. |
| PubMedID- 21994707 | chronic infection with hepatitis c virus (hcv) frequently leads to liver cirrhosis or liver cancer. |
| PubMedID- PMC3882569 | chronic infection with hepatitis c virus (hcv) induces a chronic stimulation of b lymphocytes and, in some cases, this stimulation can lead to chronic lymphoid disorders like non-hodgkin lymphoma. |
| PubMedID- 20106936 | An example is chronic infection with hepatitis c virus, where the initial infection may be asymptomatic for decades. |
| PubMedID- 22894766 | chronic infection with hepatitis c virus (hcv) is the predominant aetiology for the development of hepatocellular carcinoma (hcc) worldwide . |
| PubMedID- 23327540 | chronic infection with hepatitis c virus (hcv) is common, but underdiagnosed and undertreated worldwide. |
| PubMedID- 23315914 | chronic infection with the hepatitis c virus (hcv) is a leading cause of global morbidity and mortality. |
| PubMedID- 25198705 | chronic infection with hepatitis c virus (hcv) is associated with a large spectrum of extrahepatic manifestations (ehms), mostly immunologic/rheumatologic in nature owing to b-cell proliferation and clonal expansion. |
| PubMedID- 20929104 | Cirrhosis due to chronic infection with hepatitis c virus remains by far the most common reason for liver transplantation in north america. |
| PubMedID- 23207339 | Objective: to investigate the in vivo functional roles of the la autoantigen (la), the human homologue of the 33-kda vesicle-associated membrane protein-associated protein (hvap-33), and the subunit gamma of the human eukaryotic initiation factors 2b (eif2bgamma) as co-infection factors supporting chronic infection with hepatitis c virus (hcv). |
| PubMedID- 20163377 | Background: chronic infection with hepatitis c, genotype 2/3, responds better than other genotypes to peginterferon and ribavirin treatment. |
| PubMedID- 20332260 | Background: chronic infection with hepatitis c virus (hcv) confers increased risk for chronic renal disease, and numerous reports suggest an association with renal cell carcinoma (rcc), a cancer with rapidly rising global incidence. |
| PubMedID- 25408375 | chronic infection with hepatitis c virus (hcv) is caused by an inadequate immune response. |
| PubMedID- 22310781 | chronic infection with hepatitis c virus (hcv) is a major problem affecting a significant percentage of patients with end-stage renal failure (esrd), with a negative impact on patient survival, and associated with accelerated progression of liver damage after undergoing a kidney transplant. |
| PubMedID- 23151512 | chronic infection with hepatitis c virus (hcv) is an important cause of end stage liver disease worldwide. |
| PubMedID- 25170193 | chronic infection with hepatitis c virus (hcv) is a leading cause of liver-related morbidity and mortality worldwide and predisposes to liver fibrosis and end-stage liver complications. |
| PubMedID- 23010773 | Introduction: adverse effects appearing during combined peg-interferon and ribavirin antiviral treatment against chronic infection with the hepatitis c virus are a major cause for treatment failures and abrupt interruption. |
| PubMedID- 21477324 | chronic infection with hepatitis c virus (hcv) is a major and growing public health problem, which could easily lead to chronic liver disease, cirrhosis and even hepatocellular carcinoma 1. |
| PubMedID- 24156952 | In asymptomatic naive patients, cart is recommended if the cd4(+) lymphocyte count is <500cells/mul; if the cd4(+) lymphocyte count is >500cells/mul, cart can be delayed, although it may be considered in patients with liver cirrhosis, chronic infection due to hepatitis c virus, high cardiovascular risk, plasma viral load (pvl) >10(5)copies/ml, cd4(+) lymphocyte percentage <14%, cognitive impairment, and age >55 years. |
| PubMedID- 24103591 | A markov model was used as it allows representing the relevant stages of the natural history of the disease over time, as well as estimates for probability of progression between the several health states related to the chronic infection with hepatitis c virus. |
| PubMedID- 21760886 | chronic infection with hepatitis c virus (hcv) is an important cause of liver cancer and end-stage liver disease in the united states and worldwide . |
| PubMedID- 26357633 | chronic infection with hepatitis c virus (hcv) carries a significant global health burden in both children and adults, with approximately 3% of the world's population infected. |
| PubMedID- 22869395 | Background and aim: hepatocellular carcinoma (hcc) is the most frequent form of primary liver cancer and chronic infection with hepatitis c virus is one of the main risk factors for hcc. |
| PubMedID- 24621321 | chronic infection with hepatitis c virus (hcv) affects up to 170 million individuals worldwide 1 and may lead to progressive hepatic fibrosis and cirrhosis, with risk of liver failure and hepatocellular carcinoma. |
| PubMedID- 24069039 | chronic infection with hepatitis c virus (hcv) is increasingly recognized as a major global health problem (1, 2). |
| PubMedID- 20208985 | chronic infection with the hepatitis c virus (chc) is associated with physical and mental symptoms including fatigue and depression that adversely affect quality of life. |
| PubMedID- 25646622 | Along these lines, somewhat discouraging results have recently been reported from a phase i monotherapy trial of the hcv entry inhibitor itx-5061 given for up to 28 days in the setting of established chronic infection with the hepatitis c virus . |
| PubMedID- 25604355 | Although chronic infection with hepatitis c virus (hcv) is the leading indication for liver transplantation in the united states, graft and patient survival rates are reduced because of hcv recurrence after transplant. |
| PubMedID- 26209383 | We report on the first well-tolerated and successful use of sofosbuvir-based therapy in a patient in whom chronic infection with hepatitis c had preceded the development of b-cell non-hodgkin's lymphoma. |
| PubMedID- 21680513 | chronic infection with the hepatitis c virus (hcv) is associated with increased risk for hepatocellular carcinoma (hcc). |
| PubMedID- 22792259 | chronic infection with hepatitis c virus (hcv) is considered a major risk for chronic liver failure. |
| PubMedID- 26225247 | chronic infection with hepatitis c virus (hcv) affects about 170 million people worldwide and is a major cause of liver complications. |
| PubMedID- 23872239 | chronic infection with hepatitis c virus (hcv) is a major global health problem; there are approximately 120 to 130 million chronic infections worldwide. |
| PubMedID- 19902246 | chronic infection with the hepatitis c virus (hcv) represents one of the major causes for end-stage liver disease worldwide. |
| PubMedID- 22263340 | chronic infection with hepatitis c virus is a "silent epidemic", affecting 170 million people worldwide. |
| PubMedID- 24168254 | From 2002 to 2011, the standard of care treatment for chronic infection with hepatitis c virus (hcv) was 24 or 48 weeks of therapy with pegylated interferon-alfa (peg-ifn) and ribavirin (rbv). |
| PubMedID- 21741004 | Background/purpose: chronic infection with the hepatitis c virus (hcv) is associated with impaired lipid metabolism. |
| PubMedID- 25888935 | chronic infection with hepatitis c virus (hcv) affects approximately 170 million people worldwide, and it is associated with increased morbidity and mortality secondary to cirrhosis and hepatocarcinoma (hcc) 1. |
| PubMedID- 21461964 | chronic infections with hepatitis c virus (hcv) are frequently pronounced in the etiology of malignancies especially in hepatocellular carcinoma. |
| PubMedID- 20642483 | Sex and age differences in lipid response to chronic infection with the hepatitis c virus in the united states national health and nutrition examination surveys. |
| PubMedID- 21187906 | chronic infection with the hepatitis c virus (hcv) is amongst the most frequent causes of liver cirrhosis and hepatocellular carcinoma 1. |
| PubMedID- 24822024 | chronic infection with hepatitis c virus (hcv) affects more than 170 million people worldwide and is a leading cause of anticipated liver-related death due to the development of cirrhosis and its complications.1 in the last 10 years, standard of care anti-hcv treatment has been founded on the combination of peginterferon (peg-ifn) plus ribavirin (rbv), whose main disadvantages were suboptimal rates of sustained virological response (svr) in difficult-to-treat patients (hcv genotype 1–4, advanced liver fibrosis) and, most of all, side effects profile resulting in poor tolerability and treatment contraindication in some patient subsets (decompensated liver disease and autoimmune disorders).2 the recent availability of culture cell models provided deeper insight in understanding hcv life cycle and was the basis for the development of new drugs targeting non-structural hcv proteins involved in viral replication process, such as ns3 and ns5a/b (figure 1 and table 1). |